EGFR and metastatic neoplasm: Since so far immunotherapeutic options for CRC treatment are rather limited, with applications of anti-epidermal growth factor receptor (EGFR) mAbs and checkpoint inhibitors being restricted to the subsets of patients with metastatic disease that display rat sarcoma (RAS) wildtype and microsatellite instability-high/DNA mismatch repair deficiency, respectively, we here set out to evaluate 293C3-SDIE as a potential immunotherapeutic option for CRC.